Fetal ductus arteriosus constriction and heart failure following maternal cyclooxygenase-2 inhibitor ingestion: A case report.
- Author:
Min A LEE
1
;
Young Bok KO
;
Yun Ee RHEE
;
Mee Young CHANG
;
Hong Ryang KIL
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Chungnam National University, Daejeon, Korea. rheyun@cnu.ac.kr
- Publication Type:Case Report
- Keywords:
Ductus arteriosus;
Non-steroidal anti-inflammatory drugs;
Cyclooxygenase-2 inhibitor;
Nimesulide
- MeSH:
Anti-Inflammatory Agents, Non-Steroidal;
Cardiomegaly;
Constriction;
Cyclooxygenase 2;
Ductus Arteriosus;
Eating;
Female;
Fetal Death;
Fetal Heart;
Heart;
Heart Failure;
Maternal Exposure;
Pericardial Effusion;
Pregnancy;
Sulfonamides;
Tricuspid Valve Insufficiency
- From:Korean Journal of Obstetrics and Gynecology
2008;51(7):771-776
- CountryRepublic of Korea
- Language:English
-
Abstract:
We report a case of premature constriction of the fetal ductus arteriosus following maternal ingestion of a cyclooxygenase-2 (COX-2) inhibitor at 37 weeks' gestation. Fetal sonography at 38+2 weeks' gestation revealed tricuspid regurgitation, absent transpulmonary valve flow, right heart enlargement, and pericardial effusion. An immediate delivery resulted in a good postnatal outcome with dramatic improvement in the clinical and echocardiographic findings. Maternal exposure to Non-steroidal anti-inflammatory drugs (NSAIDs), especially late in gestation, can cause premature constriction of the ductus arteriosus, heart failure, and fetal death. Therefore, the use of NSAIDs late in gestation should be considered in limited cases with close fetal heart monitoring.
